# EDGAR Filing Document

**Accession Number:** 0000749660
**File Stem:** 0001193125-23-069167
**Filing Date:** 2023-3
**Character Count:** 10382
**Document Hash:** fc05bf88cda774d69160b3894b66e4e7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-069167.hdr.sgml**: 20230313

**ACCESSION NUMBER**: 0001193125-23-069167

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230313

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230313

**DATE AS OF CHANGE**: 20230313

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ICAD INC
- **CENTRAL INDEX KEY:** 0000749660
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 020377419
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-09341
- **FILM NUMBER:** 23728045

**BUSINESS ADDRESS:**
- **STREET 1:** 98 SPIT BROOK ROAD, SUITE 100
- **CITY:** NASHUA
- **STATE:** NH
- **ZIP:** 03062
- **BUSINESS PHONE:** 603-882-5200

**MAIL ADDRESS:**
- **STREET 1:** 98 SPIT BROOK ROAD, SUITE 100
- **CITY:** NASHUA
- **STATE:** NH
- **ZIP:** 03062

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HOWTEK INC
- **DATE OF NAME CHANGE:** 19920703

?xml version="1.0" encoding="utf-8" ? 8-K

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, DC 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### PURSUANT TO SECTION 13 OR 15(d)

#### OF THE SECURITIES EXCHANGE ACT OF 1934

#### Date of report (Date of earliest event reported): March 13, 2023

------

## iCAD, INC.

#### (Exact Name of Registrant as Specified in Its Charter)

------

#### Delaware

#### (State or Other Jurisdiction of Incorporation)

---

| | |
|:---|:---|
| **001-09341** | **02-0377419** |
| **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **98 Spit Brook Road, Suite 100, Nashua, New Hampshire** | **03062** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

(603) 882-5200

#### (Registrant's Telephone Number, Including Area Code)

#### Not Applicable

#### (Former Name or Former Address, if Changed Since Last Report)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| **Title of each class** | **Name of each exchange**<br> **on which registered** |
| Common Stock, $0.01 par value ICAD | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 2.02.** | **Results of Operations and Financial Condition.**  |

---

On March 13, 2023, iCAD, Inc. (the "Company") issued a press release providing among other things, certain preliminary, unaudited financial information, for the fourth quarter ended December 31, 2022. A copy of the press release is attached hereto as Exhibit 99.1.

Exhibit 99.1 is being furnished pursuant to Item 2.02, is not to be considered filed under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be incorporated by reference into any of the Company's previous or future filings under the Securities Act of 1933, as amended, or the Exchange Act.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.**  |

---

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit**<br> **&nbsp;&nbsp;&nbsp;&nbsp;No.&nbsp;&nbsp;&nbsp;&nbsp;** | **Exhibit Description** |
| 99.1 | [Press release dated March 13, 2023](d472491dex991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
| iCAD, INC.<br> (Registrant) | iCAD, INC.<br> (Registrant) |
| By: | /s/ Dana Brown |
|  | Dana Brown<br> President and Chief Executive Officer |

---

Date: March 13, 2023

## Exhibit 99.1

**Exhibit 99.1**![LOGO](g472491g0313070827594.jpg)

**iCAD Previews Fourth Quarter Financial Results,** 

**Full Report on March 28, 2023** 

*Company is exploring strategic options for its Therapy business line* 

NASHUA, N.H., March 13, 2023 — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the fourth quarter and year ended December 31, 2022, after the market close, and host a conference call at 4:30 PM ET on Tuesday, March 28, 2023.

Based on preliminary, unaudited financial information, the Company expects total revenue for the fourth quarter ended December 31, 2022 to be approximately $6.5 million.

The Company is implementing measures to align its cost base with changes in revenue from its ongoing transition from perpetual to subscription software licenses, while maintaining investments in key growth initiatives.

The Company has also engaged investment bankers to explore strategic options for its Therapy business line.

iCAD's consolidated financial statements for the twelve months ended December 31, 2022 are not yet available. The preliminary estimated financial information included in this press release for the fourth quarter ended December 31, 2022 is based solely on management's estimates reflecting currently available preliminary information, and remains subject to iCAD's consideration of subsequent events, particularly as it relates to material estimates and assumptions used in preparing our consolidated financial statements for the twelve months ended December 31, 2021. iCAD's final consolidated financial results as of and for the three months ended December 31, 2021 may differ materially from estimates and the interim balances set forth in this release. Furthermore, the information presented herein does not include all information necessary for an understanding of the Company's full fiscal year ended December 31, 2022.

Conference call details are as follows:

Domestic: 888-506-0062

International: 973-528-0011

Participant Access Code: 864678

Webcast: https://www.webcaster4.com/Webcast/Page/2879/47820

**About iCAD, Inc.** 

Headquartered in Nashua, NH, iCAD<sup>®</sup> is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.

**Forward-Looking Statements** 

Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company's products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI<sup>®</sup>, the benefits of the Company's products, and future prospects for the Company's technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results,

------

![LOGO](g472491g0313070827594.jpg)

performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company's ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening in light of risks of potential exposure to Covid-19, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe," "demonstrate," "intend," "expect," "estimate," "will," "continue," "anticipate," "likely," "seek," and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC's website at http://www.sec.gov.

Contact:

Media Inquiries:

Jessica Burns, iCAD

+1-201-423-4492

jburns@icadmed.com

Investor Inquiries:

iCAD Investor Relations

ir@icadmed.com